Zacks Research Predicts Reduced Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Research analysts at Zacks Research cut their Q1 2025 earnings estimates for Avanos Medical in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.19 per share for the quarter, down from their prior estimate of $0.29. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q2 2025 earnings at $0.29 EPS, Q4 2025 earnings at $0.42 EPS, Q1 2026 earnings at $0.31 EPS, Q3 2026 earnings at $0.39 EPS, Q4 2026 earnings at $0.49 EPS and FY2027 earnings at $1.43 EPS.

Separately, StockNews.com raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a report on Wednesday.

Avanos Medical Price Performance

AVNS stock opened at $14.67 on Friday. The business’s 50-day moving average is $15.83 and its two-hundred day moving average is $18.72. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. The firm has a market capitalization of $675.05 million, a P/E ratio of 43.16 and a beta of 1.17. Avanos Medical has a 1 year low of $14.25 and a 1 year high of $25.36.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.40 by $0.03. The business had revenue of $179.60 million during the quarter, compared to the consensus estimate of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%.

Insider Activity at Avanos Medical

In related news, SVP Kerr Holbrook sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total value of $106,750.00. Following the completion of the transaction, the senior vice president now directly owns 82,047 shares of the company’s stock, valued at $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.94% of the stock is currently owned by corporate insiders.

Institutional Trading of Avanos Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new position in shares of Avanos Medical in the 3rd quarter valued at $42,000. Quantbot Technologies LP acquired a new stake in shares of Avanos Medical in the 4th quarter valued at about $64,000. KBC Group NV grew its stake in Avanos Medical by 63.0% during the 3rd quarter. KBC Group NV now owns 2,833 shares of the company’s stock worth $68,000 after buying an additional 1,095 shares during the last quarter. State of Wyoming lifted its stake in Avanos Medical by 132.0% in the fourth quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after buying an additional 2,923 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Avanos Medical by 493.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock valued at $129,000 after acquiring an additional 6,714 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.